BlueCrest Capital Management’s Harvard Bioscience HBIO Stock Holding History

BlueCrest Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,997	Closed	-$200K	–	1627
2018 Q1	$200K	Buy	+3,997	New	+$179K	0.01%	1276

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlueCrest Capital Management's HBIO Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Harvard Bioscience (HBIO) in Q2 2018, closing a stake of 3,997 shares — an estimated $200K sold.

BlueCrest Capital Management first reported a position in HBIO in Q1 2018 and held it in 1 quarter. The position peaked at $200K in Q1 2018. 80 funds tracked by Wall St. Rank hold HBIO as of Q2 2018.

BlueCrest Capital Management reported no remaining Harvard Bioscience position as of Q2 2018 after selling out during the quarter.
BlueCrest Capital Management sold 3,997 Harvard Bioscience shares in Q2 2018, an estimated $200K.
BlueCrest Capital Management first reported a position in Harvard Bioscience in Q1 2018 and held it in 1 quarter.
BlueCrest Capital Management's Harvard Bioscience position peaked at $200K in Q1 2018.
80 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.